By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Nektar Therapeutics (California) 

Corporate Headquarters
455 Mission Bay Boulevard South
San Francisco  California  94158  U.S.A.
Phone: 415-482-5300, Toll Free 855-482-NKTR (6587) Fax: 415-339-5300


Nektar Therapeutics has a robust R&D pipeline and portfolio of approved partnered medicines in oncology, pain, immunology and other therapeutic areas. In the area of oncology, Nektar is developing NKTR-214, an immuno-stimulatory CD122-biased agonist, which is in Phase 1/2 clinical development for patients with solid tumors. ONZEALD™ (etirinotecan pegol), a long-acting topoisomerase I inhibitor, is being developed for patients with advanced breast cancer and brain metastases and is partnered with Daiichi Sankyo in Europe. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for MOVANTIK™ (naloxegol), the first FDA-approved once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. The product is also approved in the European Union as MOVENTIG® (naloxegol) and is indicated for adult patients with OIC who have had an inadequate response to laxatives. The AstraZeneca agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of MOVANTIK and an opioid. NKTR-181, a wholly owned mu-opioid analgesic molecule for chronic pain conditions, is in Phase 3 development. In hemophilia, Nektar has a collaboration agreement with Baxalta for ADYNOVATE™ [Antihemophilic Factor (Recombinant)], a longer-acting PEGylated Factor VIII therapeutic approved in the U.S. andJapan for patients over 12 with hemophilia A. In anti-infectives, the company has two collaborations with Bayer Healthcare, Cipro Inhale in Phase 3 for non-cystic fibrosis bronchiectasis and Amikacin Inhale in Phase 3 for patients with Gram-negative pneumonia.

Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including AstraZeneca's MOVANTIK™, Baxalta's ADYNOVATE™, UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.

Key Statistics

Ownership: Public

Web Site: Nektar
Employees: 454
Symbol: NKTR

Company News
Nektar (NKTR) Reports Financial Results For The Second Quarter Of 2017 8/9/2017 12:29:46 PM
Nektar (NKTR) To Announce Financial Results For The Second Quarter Of 2017 On Tuesday, August 8, 2017, After Close Of U.S.-Based Financial Markets 8/3/2017 12:26:40 PM
Bay Area's Nektar (NKTR) Inks $400 Million+ Autoimmune Disease Pact With Eli Lilly (LLY) 7/24/2017 5:51:24 AM
Bay Area Nektar (NKTR)' Comeback is Stalled as the EMA Rejects Breast Cancer Drug 7/21/2017 6:30:36 AM
Bay Area's Nektar Therapeutics (NKTR) Comes Back With Impressive Opiod Addiction Study Data 7/18/2017 6:20:59 AM
Nektar Therapeutics (NKTR) Presents New Preclinical Data For NKTR-358, A First-In-Class Regulatory T Cell Stimulator, At 13th World Congress Of Inflammation In London 7/10/2017 7:25:07 AM
Nektar Therapeutics (NKTR): A Sweet Or Sour Investment? 6/15/2017 6:27:24 AM
Nektar Therapeutics (NKTR) Presents New Clinical Data From Two Studies Of NKTR-214, A CD122-Biased Agonist, At 2017 ASCO Annual Meeting 6/5/2017 7:51:27 AM
New Research Collaboration Between Nektar Therapeutics (NKTR) And Takeda (TKPYY) To Explore Combination Cancer Therapy Approaches With NKTR-214, A CD122-Biased Agonist, And Five Takeda Cancer Therapy Compounds 5/22/2017 7:25:46 AM
Nektar Therapeutics (NKTR) Reports Financial Results For The First Quarter Of 2017 5/10/2017 11:09:55 AM